eFFECTOR Therapeutics Inc. (NASDAQ:EFTR) traded with a subtraction of $0.0 to $0.71 on Thursday, a downside of 0.00 percent. An average of 661,843 shares of common stock have been traded in the last five days. There was a gain of $0.0524 in the past week, and it reached a new high 14 times over the past 12 months. The last 20 days have seen an average of 567,296 shares traded, while the 50-day average volume stands at 932,534.
EFTR stock has decreased by -1.44% in the last month. The company shares reached their 1-month lowest point of $0.6020 on 08/11/23. With the stock rallying to its 52-week high on 06/06/23, shares of the company touched a low of $0.34 and a high of $1.48 in 52 weeks. It has reached a new high 10 times so far this year and achieved 66.04% or $0.2748 in price. In spite of this, the price is down -52.03% from the 52-week high.
Valuation Metrics
eFFECTOR Therapeutics Inc. (EFTRstock’s beta is 0.33. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 27.59, the price-to-book (PB) ratio at 14.20.
Financial Health
The quick ratio of eFFECTOR Therapeutics Inc. for the three months ended June 29 was 1.10, and the current ratio was 1.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 7.38 for the quarter ending June 29. eFFECTOR Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -910.50%. Its gross profit as reported stood at $35.96 million compared to revenue of $3.55 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, eFFECTOR Therapeutics Inc.’s return on assets was -129.90%.
Earnings Surprise
The company posted a net income of -$8.36 million in the quarter, while revenues were grew 17.22%. The analyst consensus anticipated eFFECTOR Therapeutics Inc.’s latest quarter earnings to come in at -$0.2 per share, but it turned out to be -$0.17, a 15.00% surprise. For the quarter, EBITDA amounted to -$7.91 million. Shareholders own equity worth $61.77 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at eFFECTOR Therapeutics Inc. (EFTR) price momentum. RSI 9-day as of the close on 23 August was 50.72%, suggesting the stock is Neutral, with historical volatility in this time frame at 69.08%.
As of today, EFTR’s price is $0.6919 +8.06% or $0.0524 from its 5-day moving average. EFTR is currently trading -7.38% lower than its 20-day SMA and +99.15% higher than its 100-day SMA. However, the stock’s current price level is -38.66% below the SMA50 and +32.53% above the SMA200.
The stochastic %K and %D were 48.12% and 43.54%, respectively, and the average true range (ATR) was 0.0696. With the 14-day stochastic at 56.40% and the average true range at 0.0721, the RSI (14) stands at 48.08%. The stock has reached 0.0131 on the 9-day MACD Oscillator while the 14-day reading was at 0.0071.
Analyst Ratings
Stifel downgraded eFFECTOR Therapeutics Inc. (NASDAQ: EFTR) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for eFFECTOR Therapeutics Inc. (EFTR) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell EFTR, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.
What is EFTR’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $10.00, with a median target of $5.50. Taking a look at these predictions, the average price target given by analysts for eFFECTOR Therapeutics Inc. (EFTR) stock is $6.58.
